Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database

A better understanding of immune-related adverse events is essential for the early detection and appropriate management of these phenomena. We conducted an observational study of cases recorded at the French reference center for hypereosinophilic syndromes and in the French national pharmacovigilanc...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Quentin Scanvion, Johana Béné, Sophie Gautier, Aurélie Grandvuillemin, Christine Le Beller, Chouki Chenaf, Nicolas Etienne, Solenn Brousseau, Alexis B. Cortot, Laurent Mortier, Delphine Staumont-Sallé, Franck Morschhauser, Alexandra Forestier, Matthieu Groh, David Launay, Eric Hachulla, Myriam Labalette, Jean-Emmanuel Kahn, Guillaume Lefèvre
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Taylor & Francis Group 2020-01-01
Serie:	OncoImmunology
Soggetti:	eosinophilia immune-related adverse events emergent adverse event immune checkpoint inhibitors
Accesso online:	http://dx.doi.org/10.1080/2162402X.2020.1722022
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!